A double blind study to investigate the clinical efficacy and safety of ragweed MATAMPL (allergy therapeutics), pollinex-R (allergy therapeutics) and placebo in patients with seasonal allergic rhinitis with ragweed allergy, in an environmental exposure chamber (EEC) model, with follow-up during a natural ragweed pollen season

Ragweed MATAMPL has been developed to provide pre-seasonal specific immunotherapy for patients with hypersensitivity to ragweed pollen (hay fever). This novel formulation is designed to provide a vaccine that will be efficacious with only four escalating dose injections administered before the start of the pollen season. In this study, the safety and efficacy of Ragweed MATAMPL will be assessed by exposing allergic subjects to Ragweed pollen in an environmental exposure chamber (EEC). Patient symptomatic response to pollen and patient quality of life in the EEC will be determined.